FY2025 EPS Estimates for Amgen Inc. (NASDAQ:AMGN) Reduced by Analyst

Amgen Inc. (NASDAQ:AMGN) – Equities researchers at William Blair lowered their FY2025 earnings per share (EPS) estimates for shares of Amgen in a research report issued on Wednesday, April 17th. William Blair analyst M. Phipps now anticipates that the medical research company will earn $19.15 per share for the year, down from their prior forecast of $19.34. The consensus estimate for Amgen’s current full-year earnings is $19.45 per share.

Several other research analysts have also issued reports on AMGN. Leerink Partnrs lowered Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 7th. StockNews.com lowered Amgen from a “buy” rating to a “hold” rating in a research report on Thursday, March 28th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $329.00 target price on shares of Amgen in a research report on Wednesday, April 3rd. Truist Financial reaffirmed a “buy” rating and set a $320.00 target price on shares of Amgen in a research report on Friday, April 12th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $350.00 target price on shares of Amgen in a research report on Thursday, February 1st. Ten analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $296.95.

Amgen Trading Up 2.4 %

Shares of NASDAQ:AMGN opened at $268.93 on Friday. The business’s 50-day moving average is $276.90 and its 200 day moving average is $281.26. Amgen has a 1 year low of $211.71 and a 1 year high of $329.72. The firm has a market capitalization of $144.12 billion, a P/E ratio of 21.53, a P/E/G ratio of 2.46 and a beta of 0.58. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, topping analysts’ consensus estimates of $4.66 by $0.05. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The firm had revenue of $8.20 billion during the quarter, compared to analysts’ expectations of $8.13 billion. During the same period in the prior year, the business posted $4.09 EPS. The firm’s quarterly revenue was up 19.8% on a year-over-year basis.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be issued a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a yield of 3.35%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s dividend payout ratio (DPR) is 72.06%.

Institutional Trading of Amgen

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Fuller & Thaler Asset Management Inc. grew its holdings in Amgen by 1.7% during the third quarter. Fuller & Thaler Asset Management Inc. now owns 11,658 shares of the medical research company’s stock worth $3,133,000 after acquiring an additional 193 shares during the period. Diversified Trust Co boosted its position in Amgen by 76.8% during the fourth quarter. Diversified Trust Co now owns 37,695 shares of the medical research company’s stock worth $10,857,000 after purchasing an additional 16,376 shares in the last quarter. Nicolet Advisory Services LLC boosted its position in Amgen by 4.4% during the third quarter. Nicolet Advisory Services LLC now owns 2,805 shares of the medical research company’s stock worth $745,000 after purchasing an additional 117 shares in the last quarter. Platform Technology Partners boosted its position in Amgen by 7.4% during the third quarter. Platform Technology Partners now owns 5,830 shares of the medical research company’s stock worth $1,567,000 after purchasing an additional 402 shares in the last quarter. Finally, Traynor Capital Management Inc. boosted its position in Amgen by 9.5% during the fourth quarter. Traynor Capital Management Inc. now owns 18,941 shares of the medical research company’s stock worth $5,455,000 after purchasing an additional 1,650 shares in the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.